Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | ![]() 5Y returns in the bottom 25% of the category. | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 6/8 | - | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 6 Years | ||
Fund Size | 1042 Cr | 83 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹200 Lumpsum ₹5000 | ||
Expense Ratio | 1.2% | 1.22% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 45 | 29 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.65%) Cipla Ltd (5.81%) Ajanta Pharma Ltd (4.4%) Dr Reddy's Laboratories Ltd (4.35%) Glenmark Pharmaceuticals Ltd (4.07%) | Sun Pharmaceuticals Industries Ltd (10.03%) Piramal Pharma Ltd (5.9%) Torrent Pharmaceuticals Ltd (5.29%) Artemis Medicare Services Ltd Ordinary Shares (5.09%) Glenmark Pharmaceuticals Ltd (4.59%) | ||
No of Sectors | 2 | 2 | ||
Top 3 Sectors | Health (98.81%) Basic Materials (1.19%) | Health (93.32%) Basic Materials (6.68%) | ||
Equity % | 99.21% | 98.03% | ||
Debt % | - | - | ||
P/E | 34.71 | 40.52 | ||
P/B | 5.47 | 5.88 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 4.21% | 5.02% | ||
3-Month Return | -3.58% | -2.46% | ||
6-Month Return | -6.27% | -5.54% | ||
1-Year Return | 22.13% | 19.78% | ||
3-Year Return | 20.25% | 16.88% | ||
5-Year Return | 23.63% | 19.64% |
Sharpe | 0.84 | 0.69 | ||
Alpha | 0.99 | -1.35 | ||
Beta | 0.95 | 0.93 | ||
Standard Deviation | 16.7 | 16.51 | ||
Information Ratio | 0.18 | -0.63 |
Description | UTI Healthcare Fund-Growth Option- Direct is an equity fund.The fund could potentially beat inflation in the long-run. | LIC MF Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Karan Doshi |